|
G |
Tslp |
thymic stromal lymphopoietin |
increases expression |
ISO |
(1->3)-beta-D-glucan increases expression of TSLP mRNA and protein in corneal epithelial cells |
RGD |
PMID:26874828 |
RGD:38549373 |
NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850
|
|
|
G |
Acan |
aggrecan |
increases expression |
ISO |
alginic acid results in increased expression of ACAN mRNA |
CTD |
PMID:16371897 |
|
NCBI chr 7:78,702,974...78,764,847
Ensembl chr 7:78,703,231...78,764,847
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
EXP |
Alginic Acid results in increased expression of ATG12 protein |
CTD |
PMID:35066102 |
|
NCBI chr18:46,865,484...46,874,683
Ensembl chr18:46,863,211...46,874,647
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
EXP |
Alginic Acid results in increased expression of ATG7 protein |
CTD |
PMID:35066102 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
EXP |
Alginic Acid results in decreased expression of BCL2 protein |
CTD |
PMID:35066102 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression |
EXP |
Alginic Acid results in decreased expression of BCL2L1 protein |
CTD |
PMID:35066102 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Becn1 |
beclin 1, autophagy related |
increases expression |
EXP |
Alginic Acid results in increased expression of BECN1 protein |
CTD |
PMID:35066102 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Casp3 |
caspase 3 |
increases expression increases cleavage |
EXP |
Alginic Acid results in increased expression of CASP3 protein Alginic Acid results in increased cleavage of CASP3 protein |
CTD |
PMID:35066102 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
Alginic Acid results in increased expression of and results in increased cleavage of CASP8 protein |
CTD |
PMID:35066102 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
increases expression |
EXP |
Alginic Acid results in increased expression of CASP9 protein |
CTD |
PMID:35066102 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Alginic Acid results in decreased expression of CAT protein |
CTD |
PMID:35066102 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Col10a1 |
collagen, type X, alpha 1 |
increases expression |
ISO |
alginic acid results in increased expression of COL10A1 mRNA |
CTD |
PMID:16371897 |
|
NCBI chr10:34,265,977...34,273,081
Ensembl chr10:34,265,977...34,273,081
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
EXP |
Alginic Acid results in increased expression of CYP17A1 protein |
CTD |
PMID:35066102 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Alginic Acid results in decreased expression of CYP19A1 protein |
CTD |
PMID:35066102 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Fshr |
follicle stimulating hormone receptor |
decreases expression |
EXP |
Alginic Acid results in decreased expression of FSHR protein |
CTD |
PMID:35066102 |
|
NCBI chr17:89,292,380...89,508,103
Ensembl chr17:89,292,380...89,508,103
|
|
G |
Gpx5 |
glutathione peroxidase 5 |
decreases expression |
EXP |
Alginic Acid results in decreased expression of GPX5 protein |
CTD |
PMID:35066102 |
|
NCBI chr13:21,470,599...21,476,897
Ensembl chr13:21,470,599...21,476,901
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
alginic acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12723939 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases lipidation |
EXP |
Alginic Acid results in increased lipidation of MAP1LC3B protein |
CTD |
PMID:35066102 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions |
EXP |
Alginic Acid results in increased expression of and results in increased cleavage of PARP1 protein |
CTD |
PMID:35066102 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Rab7 |
RAB7, member RAS oncogene family |
increases expression |
EXP |
Alginic Acid results in increased expression of RAB7 protein |
CTD |
PMID:35066102 |
|
NCBI chr 6:87,976,088...88,022,252
Ensembl chr 6:87,976,088...88,022,252
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
decreases expression |
EXP |
Alginic Acid results in decreased expression of SOD1 protein |
CTD |
PMID:35066102 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
decreases expression |
EXP |
Alginic Acid results in decreased expression of SOD2 protein |
CTD |
PMID:35066102 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
EXP |
Alginic Acid results in decreased expression of SQSTM1 protein |
CTD |
PMID:35066102 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Alginic Acid results in decreased expression of STAR protein |
CTD |
PMID:35066102 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
alginic acid inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]; alginic acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; alginic acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12723939 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of ABCA1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases phosphorylation |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of AKT1 protein] Chitosan results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:28732690 PMID:36706893 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alad |
aminolevulinate, delta-, dehydratase |
multiple interactions |
ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of ALAD protein] |
CTD |
PMID:22704994 |
|
NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
increases expression |
ISO |
Chitosan results in increased expression of ALPL mRNA; Chitosan results in increased expression of ALPL protein |
CTD |
PMID:25246786 |
|
NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of AOX1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in decreased expression of AOX1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 1:58,068,963...58,145,569
Ensembl chr 1:58,069,090...58,145,572
|
|
G |
Arb2a |
ARB2 cotranscriptional regulator A |
multiple interactions increases expression |
ISO |
ARB2A protein affects the reaction [Chitosan results in decreased expression of CPE protein]; ARB2A protein affects the reaction [Chitosan results in decreased expression of MMP9 protein]; ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK1 protein]; ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK3 protein] Chitosan results in increased expression of ARB2A mRNA |
CTD |
PMID:36706893 |
|
NCBI chr13:77,856,799...78,314,359
Ensembl chr13:77,850,152...78,314,354
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
EXP ISO |
[Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in increased expression of BAX protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of BAX protein] |
CTD |
PMID:18567086 PMID:30928397 PMID:38211767 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
EXP ISO |
[Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in decreased expression of BCL2 protein [Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of BCL2 protein]; [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:18567086 PMID:28732690 PMID:30928397 PMID:38211767 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Chitosan results in increased expression of BGLAP mRNA |
CTD |
PMID:25246786 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of CASP2 mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Chitosan metabolite inhibits the reaction [Copper results in increased activity of CASP3 protein] Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Chitosan inhibits the reaction [carbendazim results in increased expression of CASP3 protein]; Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of CASP3 mRNA]] |
CTD |
PMID:25542178 PMID:30928397 PMID:35705592 PMID:38369055 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of CASP7 mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein] |
CTD |
PMID:30928397 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Chitosan analog co-treated with Quercetin] inhibits the reaction [ochratoxin A results in decreased activity of CAT protein]; [Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Chitosan analog inhibits the reaction [ochratoxin A results in decreased activity of CAT protein]; Chitosan inhibits the reaction [carbendazim results in decreased expression of CAT protein]; Chitosan inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:12679053 PMID:22704994 PMID:27923682 PMID:30928397 PMID:35705592 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Clec7a |
C-type lectin domain family 7, member a |
multiple interactions decreases expression |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA] Chitosan results in decreased expression of CLEC7A mRNA |
CTD |
PMID:21329777 |
|
NCBI chr 6:129,438,554...129,449,748
Ensembl chr 6:129,438,554...129,449,742
|
|
G |
Col15a1 |
collagen, type XV, alpha 1 |
decreases expression |
ISO |
Chitosan results in decreased expression of COL15A1 mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 4:47,207,744...47,313,165
Ensembl chr 4:47,208,161...47,313,167
|
|
G |
Cpe |
carboxypeptidase E |
multiple interactions decreases expression |
ISO |
ARB2A protein affects the reaction [Chitosan results in decreased expression of CPE protein] Chitosan results in decreased expression of CPE mRNA; Chitosan results in decreased expression of CPE protein |
CTD |
PMID:36706893 |
|
NCBI chr 8:65,045,576...65,146,143
Ensembl chr 8:65,045,576...65,146,088
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of CTNNB1 protein] |
CTD |
PMID:28732690 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:38211767 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Fish Oils promotes the reaction [Chitosan inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]] |
CTD |
PMID:28987369 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
Chitosan results in increased expression of DKK1 mRNA |
CTD |
PMID:36706893 |
|
NCBI chr19:30,523,276...30,526,896
Ensembl chr19:30,523,263...30,527,065
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Foxo3 |
forkhead box O3 |
decreases phosphorylation |
ISO |
Chitosan results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:36706893 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Gcg |
glucagon |
increases expression increases secretion multiple interactions |
ISO |
Chitosan results in increased expression of GCG mRNA Chitosan results in increased secretion of GCG protein SB 203580 inhibits the reaction [Chitosan results in increased expression of GCG mRNA]; SB 203580 inhibits the reaction [Chitosan results in increased secretion of GCG protein] |
CTD |
PMID:23611362 |
|
NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1, soluble |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased secretion of GOT1 protein] |
CTD |
PMID:35705592 |
|
NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased secretion of GPT protein] |
CTD |
PMID:35705592 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO |
[Chitosan analog co-treated with Quercetin] inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; [Chitosan analog co-treated with Quercetin] results in increased expression of GPX1 mRNA; Chitosan analog inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] Chitosan analog results in increased expression of GPX1 mRNA |
CTD |
PMID:27923682 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in decreased expression of GSDMD mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of GSK3B protein] |
CTD |
PMID:28732690 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
ISO |
Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of GSR mRNA] |
CTD |
PMID:30928397 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Chitosan metabolite results in decreased susceptibility to Copper] which results in increased expression of HMOX1 mRNA; [Chitosan metabolite results in decreased susceptibility to Copper] which results in increased expression of HMOX1 protein Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 mRNA]; Chitosan inhibits the reaction [carbendazim results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:25542178 PMID:30928397 PMID:35705592 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases secretion |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Chitosan results in increased secretion of IL10 protein |
CTD |
PMID:21329777 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of IL1B mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions |
ISO |
Chitosan results in increased secretion of IL6 protein Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:21329777 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased expression of KEAP1 mRNA] |
CTD |
PMID:35705592 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:36706893 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of MAPK3 protein] ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:28732690 PMID:36706893 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [Aminolevulinic Acid analog results in increased activity of MMP2 protein] |
CTD |
PMID:18806744 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
ARB2A protein affects the reaction [Chitosan results in decreased expression of MMP9 protein] Chitosan results in decreased expression of MMP9 mRNA; Chitosan results in decreased expression of MMP9 protein |
CTD |
PMID:36706893 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions affects localization |
ISO |
[Chitosan metabolite results in decreased susceptibility to Copper] which results in increased phosphorylation of NFE2L2 protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]; Chitosan inhibits the reaction [carbendazim results in decreased expression of NFE2L2 mRNA]; pyrazolanthrone inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; SB 203580 inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]] Chitosan analog affects the localization of NFE2L2 protein |
CTD |
PMID:25542178 PMID:30928397 PMID:35705592 PMID:38211767 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of NLRP3 mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased expression of NOS2 protein] |
CTD |
PMID:35705592 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of NQO1 mRNA] |
CTD |
PMID:30928397 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in increased expression of NR1H3 protein] |
CTD |
PMID:28987369 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
decreases phosphorylation |
ISO |
Chitosan results in decreased phosphorylation of PIK3CA protein |
CTD |
PMID:36706893 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases phosphorylation |
ISO |
Chitosan results in decreased phosphorylation of PIK3R1 protein |
CTD |
PMID:36706893 |
|
NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein] |
CTD |
PMID:28987369 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
increases expression |
ISO |
Chitosan results in increased expression of PPARGC1A mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of RELA protein]; Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of RELA mRNA]] |
CTD |
PMID:28732690 PMID:38369055 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression |
ISO |
Chitosan results in increased expression of RUNX2 mRNA; Chitosan results in increased expression of RUNX2 protein |
CTD |
PMID:25246786 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions increases expression |
ISO |
[Chitosan analog co-treated with Quercetin] results in increased expression of SOD1 mRNA; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of SOD1 mRNA] Chitosan analog results in increased expression of SOD1 mRNA |
CTD |
PMID:27923682 PMID:30928397 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sparcl1 |
SPARC-like 1 |
decreases expression |
ISO |
Chitosan results in decreased expression of SPARCL1 mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 5:104,226,974...104,261,954
Ensembl chr 5:104,226,977...104,261,599
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Chitosan results in increased expression of SPP1 mRNA |
CTD |
PMID:25246786 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of STAR mRNA] |
CTD |
PMID:38211767 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased expression of TH protein] |
CTD |
PMID:22704994 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of TLR2 mRNA] Chitosan results in decreased expression of TLR2 mRNA |
CTD |
PMID:21329777 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression multiple interactions |
ISO |
Chitosan results in decreased expression of TLR4 mRNA Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of TLR4 mRNA] |
CTD |
PMID:21329777 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Chitosan results in increased secretion of TNF protein |
CTD |
PMID:21329777 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
multiple interactions |
ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased expression of TPH1 protein] |
CTD |
PMID:22704994 |
|
NCBI chr 7:46,294,065...46,321,961
Ensembl chr 7:46,294,065...46,321,961
|
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
[Dextrans co-treated with ferrite analog] results in increased expression of IL10 mRNA |
CTD |
PMID:26576301 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
EXP |
[Dextrans co-treated with ferrite analog] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:26576301 |
|
NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Probenecid binds to Dextrans] inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein] |
CTD |
PMID:30102254 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Slc31a2 |
solute carrier family 31, member 2 |
decreases uptake |
EXP |
SLC31A2 protein results in decreased uptake of Dextrans |
CTD |
PMID:20930109 |
|
NCBI chr 4:62,198,630...62,216,649
Ensembl chr 4:62,180,799...62,216,648
|
|
G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
multiple interactions |
EXP |
[Dextrans co-treated with ferrite analog] results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:26576301 |
|
NCBI chr 4:144,938,938...144,973,453
Ensembl chr 4:144,940,033...144,973,440
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc5 |
ATP-binding cassette, sub-family C member 5 |
increases export multiple interactions |
ISO |
ABCC5 protein results in increased export of Hyaluronic Acid [Curcumin analog binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [Curcumin binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [xanthohumol binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; Curcumin analog inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; Curcumin inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; xanthohumol inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144
|
|
G |
Abra |
actin-binding Rho activating protein |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ABRA protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:41,728,689...41,733,116
Ensembl chr15:41,727,472...41,733,116
|
|
G |
Acan |
aggrecan |
multiple interactions |
EXP |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of ACAN mRNA |
CTD |
PMID:23595953 |
|
NCBI chr 7:78,702,974...78,764,847
Ensembl chr 7:78,703,231...78,764,847
|
|
G |
Acat2 |
acetyl-Coenzyme A acetyltransferase 2 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACAT2 protein] Hyaluronic Acid analog results in decreased expression of ACAT2 protein |
CTD |
PMID:23178681 |
|
NCBI chr17:13,161,929...13,179,612
Ensembl chr17:13,161,777...13,179,634
|
|
G |
Aco2 |
aconitase 2, mitochondrial |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ACO2 protein |
CTD |
PMID:23178681 |
|
NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
ISO |
[CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31285260 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Actb |
actin, beta |
multiple interactions affects expression |
ISO |
Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide results in decreased expression of ACTB protein] Hyaluronic Acid analog affects the expression of ACTB protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTC1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:113,877,763...113,883,356
Ensembl chr 2:113,877,763...113,884,029
|
|
G |
Actg2 |
actin, gamma 2, smooth muscle, enteric |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTG2 protein] Hyaluronic Acid analog results in decreased expression of ACTG2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:83,489,891...83,513,233
Ensembl chr 6:83,489,887...83,513,247
|
|
G |
Actr3 |
ARP3 actin-related protein 3 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTR3 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:125,320,642...125,363,464
Ensembl chr 1:125,320,642...125,363,464
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
increases abundance |
ISO |
ALB protein results in increased abundance of Hyaluronic Acid |
CTD |
PMID:16642209 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Anxa1 |
annexin A1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of ANXA1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ANXA3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:96,941,257...96,993,825
Ensembl chr 5:96,941,198...96,993,825
|
|
G |
Anxa4 |
annexin A4 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA5 protein] Hyaluronic Acid analog results in decreased expression of ANXA5 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:36,503,072...36,530,036
Ensembl chr 3:36,503,072...36,530,043
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in increased expression of ARHGAP29 protein [Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of ARHGAP29 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:121,746,752...121,810,326
Ensembl chr 3:121,746,190...121,810,402
|
|
G |
Atg5 |
autophagy related 5 |
increases cleavage multiple interactions |
ISO |
Hyaluronic Acid results in increased cleavage of ATG5 protein roxadustat promotes the reaction [Hyaluronic Acid results in increased cleavage of ATG5 protein] |
CTD |
PMID:27082295 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Atic |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of ATIC protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATIC protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:71,596,315...71,618,562
Ensembl chr 1:71,596,309...71,618,790
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP5F1A protein] Hyaluronic Acid analog results in decreased expression of ATP5F1A protein |
CTD |
PMID:23178681 |
|
NCBI chr18:77,861,468...77,870,569
Ensembl chr18:77,861,429...77,870,569
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ATP5F1B protein |
CTD |
PMID:23178681 |
|
NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid results in increased expression of BNIP3 protein roxadustat promotes the reaction [Hyaluronic Acid results in increased expression of BNIP3 protein] |
CTD |
PMID:27082295 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of CALR protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Calu |
calumenin |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of CALU protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CALU protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:29,348,105...29,376,674
Ensembl chr 6:29,348,068...29,377,109
|
|
G |
Camk1 |
calcium/calmodulin-dependent protein kinase I |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAMK1 protein] Hyaluronic Acid analog results in decreased expression of CAMK1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:113,311,085...113,320,883
Ensembl chr 6:113,311,085...113,320,945
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAR3 protein] Hyaluronic Acid analog results in decreased expression of CAR3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583
|
|
G |
Casp1 |
caspase 1 |
increases cleavage |
ISO |
Hyaluronic Acid results in increased cleavage of CASP1 protein |
CTD |
PMID:33383130 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] |
CTD |
PMID:17879260 PMID:19047049 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Diclofenac co-treated with Hyaluronic Acid] results in increased activity of CASP8 protein |
CTD |
PMID:20237495 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid] |
CTD |
PMID:23692848 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases secretion |
EXP |
Hyaluronic Acid analog results in increased secretion of CCL5 protein |
CTD |
PMID:9278343 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cct2 |
chaperonin containing TCP1 subunit 2 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT2 protein] Hyaluronic Acid analog results in decreased expression of CCT2 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:116,886,902...116,899,757
Ensembl chr10:116,886,906...116,899,719
|
|
G |
Cct4 |
chaperonin containing TCP1 subunit 4 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:22,940,593...22,953,336
Ensembl chr11:22,940,519...22,953,780
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT5 protein] Hyaluronic Acid analog results in decreased expression of CCT5 protein |
CTD |
PMID:23178681 |
|
NCBI chr15:31,590,946...31,601,992
Ensembl chr15:31,590,946...31,601,950
|
|
G |
Cd44 |
CD44 antigen |
multiple interactions increases expression affects binding |
ISO EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU protein; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR protein; [Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein; Hyaluronic Acid analog binds to and results in increased activity of CD44 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] Hyaluronic Acid analog affects the localization of [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog promotes the reaction [MAP3K1 protein binds to CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of CD44 protein]; Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]; Verapamil inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]] Hyaluronic Acid metabolite results in increased expression of CD44 mRNA; Hyaluronic Acid metabolite results in increased expression of CD44 protein |
CTD |
PMID:9929743 PMID:12402308 PMID:19047049 PMID:20159036 PMID:23692848 PMID:31285260 More...
|
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cfl1 |
cofilin 1, non-muscle |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CFL1 protein] Hyaluronic Acid analog results in decreased expression of CFL1 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Diclofenac co-treated with Hyaluronic Acid] results in decreased expression of CFLAR protein |
CTD |
PMID:20237495 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
increases export multiple interactions |
ISO |
CFTR protein results in increased export of Hyaluronic Acid Curcumin analog inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid]; xanthohumol inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Cnn3 |
calponin 3, acidic |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of CNN3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:121,220,190...121,251,854
Ensembl chr 3:121,220,146...121,251,856
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions |
EXP |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of COL2A1 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of COPS4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:100,666,223...100,695,668
Ensembl chr 5:100,666,175...100,695,669
|
|
G |
Coq7 |
demethyl-Q 7 |
multiple interactions increases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] affects the expression of COQ7 protein Hyaluronic Acid analog results in increased expression of COQ7 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:118,108,881...118,132,529
Ensembl chr 7:118,108,882...118,132,579
|
|
G |
Cpox |
coproporphyrinogen oxidase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CPOX protein] |
CTD |
PMID:23178681 |
|
NCBI chr16:58,490,571...58,500,754
Ensembl chr16:58,490,655...58,537,999
|
|
G |
Cth |
cystathionine gamma lyase |
multiple interactions |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of CTH protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
[acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of CXCL8 protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of CXCL8 protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of CXCL8 protein |
CTD |
PMID:25053413 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Hyaluronic Acid inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:30856093 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of DLD protein |
CTD |
PMID:23178681 |
|
NCBI chr12:31,381,561...31,401,470
Ensembl chr12:31,381,276...31,401,452
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of DNAJA1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:40,722,468...40,734,965
Ensembl chr 4:40,722,150...40,737,149
|
|
G |
Dstn |
destrin |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of DSTN protein] Hyaluronic Acid analog results in decreased expression of DSTN protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:143,757,251...143,785,244
Ensembl chr 2:143,757,240...143,785,244
|
|
G |
Eci2 |
enoyl-Coenzyme A delta isomerase 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of ECI2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr13:35,161,731...35,211,098
Ensembl chr13:35,161,731...35,211,079
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EEF1G protein] |
CTD |
PMID:23178681 |
|
NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of EEF2 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EEF2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:81,012,465...81,018,343
Ensembl chr10:81,012,465...81,018,332
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of EIF4E protein |
CTD |
PMID:16864594 |
|
NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ENO1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336 Ensembl chr18:150,321,178...150,333,336
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ERP29 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:121,582,816...121,590,537
Ensembl chr 5:121,566,653...121,590,569
|
|
G |
Esd |
esterase D/formylglutathione hydrolase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESD protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:74,969,591...74,988,205
Ensembl chr14:74,969,737...74,988,205
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EZR protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
EXP |
Hyaluronic Acid analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 6:127,049,865...127,059,257
Ensembl chr 6:127,049,865...127,058,371
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases chemical synthesis |
ISO |
FGF7 protein results in increased chemical synthesis of Hyaluronic Acid |
CTD |
PMID:14506240 |
|
NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in increased expression of FGG protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of FGG protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:82,915,031...82,922,363
Ensembl chr 3:82,915,031...82,922,356
|
|
G |
Fkbp4 |
FK506 binding protein 4 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of FKBP4 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of FKBP4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:128,407,066...128,415,619
Ensembl chr 6:128,406,698...128,415,640
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of FSCN1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of FSCN1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:142,946,110...142,958,944
Ensembl chr 5:142,946,098...142,958,940
|
|
G |
Fshb |
follicle stimulating hormone beta |
multiple interactions increases chemical synthesis |
ISO |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fubp1 |
far upstream element (FUSE) binding protein 1 |
multiple interactions affects expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of FUBP1 protein Hyaluronic Acid analog affects the expression of FUBP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:151,916,059...151,942,467
Ensembl chr 3:151,916,059...151,942,463
|
|
G |
Gab1 |
growth factor receptor bound protein 2-associated protein 1 |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of GAB1 protein |
CTD |
PMID:16864594 |
|
NCBI chr 8:81,491,060...81,607,151
Ensembl chr 8:81,491,063...81,607,148
|
|
G |
Gdi1 |
GDP dissociation inhibitor 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GDI1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:73,348,618...73,355,473
Ensembl chr X:73,348,604...73,355,468
|
|
G |
Glrx3 |
glutaredoxin 3 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of GLRX3 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GLRX3 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:137,039,302...137,071,360
Ensembl chr 7:137,039,343...137,070,323
|
|
G |
Gnb1 |
guanine nucleotide binding protein (G protein), beta 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GNB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:155,575,514...155,643,726
Ensembl chr 4:155,575,818...155,643,726
|
|
G |
Gnb2 |
guanine nucleotide binding protein (G protein), beta 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GNB2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:137,526,389...137,533,085
Ensembl chr 5:137,526,389...137,531,772
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1, soluble |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of GOT1 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044
|
|
G |
Gsdmd |
gasdermin D |
increases expression increases cleavage |
ISO |
Hyaluronic Acid results in increased expression of GSDMD mRNA Hyaluronic Acid results in increased cleavage of GSDMD protein |
CTD |
PMID:33383130 |
|
NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257
|
|
G |
Gsn |
gelsolin |
multiple interactions decreases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of GSN protein Hyaluronic Acid analog results in decreased expression of GSN protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:35,146,371...35,197,914
Ensembl chr 2:35,146,392...35,197,904
|
|
G |
Gucy2f |
guanylate cyclase 2f |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GUCY2F protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:140,862,282...140,980,399
Ensembl chr X:140,864,156...140,979,927
|
|
G |
Has1 |
hyaluronan synthase 1 |
increases expression |
ISO |
Hyaluronic Acid metabolite results in increased expression of HAS1 mRNA; Hyaluronic Acid metabolite results in increased expression of HAS1 protein |
CTD |
PMID:31226360 |
|
NCBI chr17:18,063,588...18,075,450
Ensembl chr17:18,063,585...18,075,467
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases chemical synthesis affects abundance multiple interactions |
ISO EXP |
HAS2 protein results in increased chemical synthesis of Hyaluronic Acid HAS2 protein affects the abundance of Hyaluronic Acid [IL1B protein results in increased expression of HAS2 protein] which results in increased chemical synthesis of Hyaluronic Acid |
CTD |
PMID:11318944 PMID:31285260 |
|
NCBI chr15:56,529,023...56,557,942
Ensembl chr15:56,529,023...56,557,935
|
|
G |
Has3 |
hyaluronan synthase 3 |
multiple interactions increases expression |
EXP ISO |
[HAS3 protein affects the susceptibility to Carbon Tetrachloride] which affects the abundance of Hyaluronic Acid; HAS3 protein affects the reaction [Carbon Tetrachloride results in increased abundance of Hyaluronic Acid] Hyaluronic Acid metabolite results in increased expression of HAS3 mRNA; Hyaluronic Acid metabolite results in increased expression of HAS3 protein |
CTD |
PMID:27042213 PMID:31226360 |
|
NCBI chr 8:107,596,874...107,609,534
Ensembl chr 8:107,596,874...107,611,198
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression multiple interactions |
ISO |
Hyaluronic Acid results in increased expression of HIF1A protein roxadustat promotes the reaction [Hyaluronic Acid results in increased expression of HIF1A protein] |
CTD |
PMID:27082295 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMBS protein] Hyaluronic Acid analog results in decreased expression of HMBS protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:44,247,645...44,255,525
Ensembl chr 9:44,247,636...44,255,525
|
|
G |
Hmmr |
hyaluronan mediated motility receptor (RHAMM) |
multiple interactions |
ISO |
Hyaluronic Acid binds to and results in increased activity of HMMR protein |
CTD |
PMID:16864594 |
|
NCBI chr11:40,592,215...40,624,290
Ensembl chr11:40,592,222...40,624,249
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HNRNPA2B1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:51,437,414...51,448,054
Ensembl chr 6:51,437,912...51,446,874
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HNRNPH1 protein] Hyaluronic Acid analog results in decreased expression of HNRNPH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:50,266,084...50,277,355
Ensembl chr11:50,267,817...50,277,355
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HNRNPK protein |
CTD |
PMID:23178681 |
|
NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSP90AA1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of HSP90B1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSP90B1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa5 |
heat shock protein 5 |
affects expression multiple interactions |
ISO |
Hyaluronic Acid analog affects the expression of HSPA5 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSPA5 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSPA8 protein] Hyaluronic Acid analog results in decreased expression of HSPA8 protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hspb1 |
heat shock protein 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HSPB1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HSPD1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Idh1 |
isocitrate dehydrogenase 1 (NADP+), soluble |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of IDH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of IDH2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of IDO1 protein] Hyaluronic Acid analog results in decreased expression of IDO1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Hyaluronic Acid inhibits the reaction [Acetaminophen results in increased expression of IFNG protein] |
CTD |
PMID:18237725 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il12b |
interleukin 12b |
increases secretion |
EXP |
Hyaluronic Acid analog results in increased secretion of IL12B protein |
CTD |
PMID:9278343 |
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il1b |
interleukin 1 beta |
increases abundance increases expression multiple interactions |
ISO EXP |
IL1B protein results in increased abundance of Hyaluronic Acid Hyaluronic Acid results in increased expression of IL1B mRNA [Hyaluronic Acid co-treated with resveratrol] results in decreased expression of IL1B mRNA Hyaluronic Acid metabolite results in increased expression of IL1B mRNA; Hyaluronic Acid metabolite results in increased expression of IL1B protein [acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of IL1B protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein]; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein; [IL1B protein results in increased expression of HAS2 protein] which results in increased chemical synthesis of Hyaluronic Acid; [Lipopolysaccharides results in decreased activity of TLR4 protein] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein]; Sulindac inhibits the reaction [IL1B protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:11318944 PMID:23595953 PMID:23692848 PMID:25053413 PMID:33383130 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of IL6 protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL6 protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL6 protein |
CTD |
PMID:25053413 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
increases expression |
ISO |
Hyaluronic Acid results in increased expression of IRAK3 protein |
CTD |
PMID:15728517 |
|
NCBI chr10:119,977,553...120,038,035
Ensembl chr10:119,977,553...120,038,035
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Hyaluronic Acid] |
CTD |
PMID:25561734 |
|
NCBI chr14:30,651,137...30,665,246
Ensembl chr14:30,651,137...30,665,246
|
|
G |
Jun |
jun proto-oncogene |
increases phosphorylation |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of JUN protein |
CTD |
PMID:12402308 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Krt10 |
keratin 10 |
multiple interactions increases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of KRT10 protein] Hyaluronic Acid analog results in increased expression of KRT10 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:99,276,080...99,288,631
Ensembl chr11:99,276,080...99,280,190
|
|
G |
Lap3 |
leucine aminopeptidase 3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of LAP3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:45,650,716...45,670,033
Ensembl chr 5:45,650,716...45,670,033
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LDHB protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:142,435,975...142,453,683
Ensembl chr 6:142,435,975...142,453,683
|
|
G |
Lgals1 |
lectin, galactose binding, soluble 1 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in increased expression of LGALS1 protein Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide results in decreased expression of LGALS1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:78,810,925...78,814,665
Ensembl chr15:78,810,925...78,814,665
|
|
G |
Lmna |
lamin A |
multiple interactions increases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LMNA protein] Hyaluronic Acid analog results in increased expression of LMNA protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:88,388,455...88,413,842
Ensembl chr 3:88,387,454...88,417,263
|
|
G |
Lrpap1 |
low density lipoprotein receptor-related protein associated protein 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LRPAP1 protein] Hyaluronic Acid analog results in decreased expression of LRPAP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:35,248,834...35,263,043
Ensembl chr 5:35,248,845...35,263,110
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases cleavage |
ISO |
roxadustat promotes the reaction [Hyaluronic Acid results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:27082295 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
increases phosphorylation |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:12402308 |
|
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
|
|
G |
Map2k2 |
mitogen-activated protein kinase kinase 2 |
increases phosphorylation |
ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAP2K2 protein |
CTD |
PMID:12402308 |
|
NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
multiple interactions |
EXP |
Hyaluronic Acid analog affects the localization of [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog promotes the reaction [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog results in increased phosphorylation of and results in increased activity of MAP3K1 protein |
CTD |
PMID:20159036 |
|
NCBI chr13:111,882,962...111,954,803
Ensembl chr13:111,882,962...111,945,527
|
|
G |
Map3k3 |
mitogen-activated protein kinase kinase kinase 3 |
multiple interactions |
EXP |
MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr11:105,975,358...106,047,482
Ensembl chr11:105,975,439...106,046,272
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Hyaluronic Acid analog results in increased phosphorylation of MAPK1 protein MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; U 0126 inhibits the reaction [Hyaluronic Acid analog results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12402308 PMID:20159036 PMID:20633555 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
Hyaluronic Acid analog results in increased phosphorylation of MAPK3 protein MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; U 0126 inhibits the reaction [Hyaluronic Acid analog results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12402308 PMID:20159036 PMID:20633555 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
EXP |
MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr11:61,379,638...61,385,101
Ensembl chr11:61,379,638...61,385,232
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of MFN1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:32,583,594...32,633,384
Ensembl chr 3:32,583,614...32,633,388
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
EXP |
[Hyaluronic Acid co-treated with resveratrol] results in decreased expression of MMP13 mRNA Hyaluronic Acid metabolite results in increased expression of MMP13 mRNA; Hyaluronic Acid metabolite results in increased expression of MMP13 protein |
CTD |
PMID:23595953 PMID:23692848 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions |
EXP |
[Hyaluronic Acid co-treated with Resveratrol] results in decreased expression of MMP1 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
affects activity |
EXP |
Hyaluronic Acid affects the activity of MMP2 protein |
CTD |
PMID:15597151 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
EXP |
[Hyaluronic Acid co-treated with resveratrol] results in decreased expression of MMP3 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
affects activity |
EXP |
Hyaluronic Acid affects the activity of MMP9 protein |
CTD |
PMID:15597151 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein] |
CTD |
PMID:14697411 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mrps7 |
mitchondrial ribosomal protein S7 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of MRPS7 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:115,494,966...115,498,862
Ensembl chr11:115,494,751...115,498,862
|
|
G |
Mus81 |
MUS81 structure-specific endonuclease subunit |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MUS81 protein] Hyaluronic Acid analog results in decreased expression of MUS81 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:5,532,589...5,538,461
Ensembl chr19:5,532,373...5,538,430
|
|
G |
Myl12a |
myosin, light chain 12A, regulatory, non-sarcomeric |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MYL12A protein] Hyaluronic Acid analog results in decreased expression of MYL12A protein |
CTD |
PMID:23178681 |
|
NCBI chr17:71,300,788...71,309,528
Ensembl chr17:71,300,651...71,309,873
|
|
G |
Myl12b |
myosin, light chain 12B, regulatory |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of MYL12B protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MYL12B protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:71,280,958...71,297,511
Ensembl chr17:71,280,128...71,297,885
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP ISO |
Hyaluronic Acid metabolite results in increased activity of [NFKB1 protein binds to RELA protein] [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein] |
CTD |
PMID:17879260 PMID:23692848 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions decreases phosphorylation |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein] Hyaluronic Acid results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:17879260 PMID:33383130 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
increases expression |
ISO |
Hyaluronic Acid results in increased expression of NLRP3 mRNA; Hyaluronic Acid results in increased expression of NLRP3 protein |
CTD |
PMID:33383130 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of NME1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NME1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:93,849,751...93,859,341
Ensembl chr11:93,847,805...93,859,347
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NME2 protein] Hyaluronic Acid analog results in decreased expression of NME2 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:93,840,640...93,847,082
Ensembl chr11:93,840,640...93,847,085
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
affects expression increases expression |
EXP |
Hyaluronic Acid affects the expression of NOS2 mRNA Hyaluronic Acid metabolite results in increased expression of NOS2 mRNA; Hyaluronic Acid metabolite results in increased expression of NOS2 protein |
CTD |
PMID:15597151 PMID:23692848 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
ISO |
Hyaluronic Acid results in decreased expression of NR1D1 mRNA |
CTD |
PMID:17075855 |
|
NCBI chr11:98,658,758...98,666,233
Ensembl chr11:98,658,758...98,666,159
|
|
G |
Nrxn1 |
neurexin I |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NRXN1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:90,341,072...91,400,587
Ensembl chr17:90,341,059...91,400,499
|
|
G |
Optn |
optineurin |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of OPTN protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:5,023,902...5,069,210
Ensembl chr 2:5,025,453...5,068,862
|
|
G |
Pde4d |
phosphodiesterase 4D, cAMP specific |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PDE4D protein |
CTD |
PMID:23178681 |
|
NCBI chr13:108,790,711...110,092,503
Ensembl chr13:108,586,482...110,089,995
|
|
G |
Pdia3 |
protein disulfide isomerase associated 3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PDIA3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168
|
|
G |
Pdia6 |
protein disulfide isomerase associated 6 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PDIA6 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:17,316,590...17,334,786
Ensembl chr12:17,316,546...17,334,771
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PGAM1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr19:41,900,310...41,907,104
Ensembl chr19:41,900,362...41,907,099
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PGK1 protein |
CTD |
PMID:23178681 |
|
NCBI chr X:105,230,706...105,247,305
Ensembl chr X:105,230,706...105,247,305
|
|
G |
Pgls |
6-phosphogluconolactonase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PGLS protein] |
CTD |
PMID:23178681 |
|
NCBI chr 8:72,044,828...72,048,911
Ensembl chr 8:72,044,820...72,053,736
|
|
G |
Phb1 |
prohibitin 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PHB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:95,557,783...95,571,599
Ensembl chr11:95,557,783...95,571,599
|
|
G |
Phgdh |
3-phosphoglycerate dehydrogenase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PHGDH protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:98,220,487...98,247,285
Ensembl chr 3:98,220,486...98,247,306
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of PIK3CA protein |
CTD |
PMID:16864594 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pitpna |
phosphatidylinositol transfer protein, alpha |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PITPNA protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:75,478,889...75,519,630
Ensembl chr11:75,478,923...75,519,630
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
[Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU protein |
CTD |
PMID:12402308 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR protein |
CTD |
PMID:12402308 |
|
NCBI chr 7:24,161,857...24,175,393
Ensembl chr 7:24,161,909...24,175,393
|
|
G |
Pls3 |
plastin 3 (T-isoform) |
multiple interactions increases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of PLS3 protein Hyaluronic Acid analog results in increased expression of PLS3 protein |
CTD |
PMID:23178681 |
|
NCBI chr X:74,829,259...74,918,788
Ensembl chr X:74,829,260...74,918,788
|
|
G |
Ppia |
peptidylprolyl isomerase A |
multiple interactions decreases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of PPIA protein Hyaluronic Acid analog results in decreased expression of PPIA protein |
CTD |
PMID:23178681 |
|
NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of PPP1CA protein |
CTD |
PMID:23178681 |
|
NCBI chr19:4,242,173...4,245,418
Ensembl chr19:4,242,064...4,245,419
|
|
G |
Prdx1 |
peroxiredoxin 1 |
affects expression |
ISO |
Hyaluronic Acid analog affects the expression of PRDX1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
|
|
G |
Prdx2 |
peroxiredoxin 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PRDX2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:85,696,251...85,701,440
Ensembl chr 8:85,696,216...85,701,463
|
|
G |
Prdx6 |
peroxiredoxin 6 |
multiple interactions affects expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PRDX6 protein] Hyaluronic Acid analog affects the expression of PRDX6 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:161,067,682...161,078,780
Ensembl chr 1:161,067,682...161,078,789
|
|
G |
Prph |
peripherin |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PRPH protein |
CTD |
PMID:23178681 |
|
NCBI chr15:98,951,452...98,956,858
Ensembl chr15:98,953,055...98,956,859
|
|
G |
Psmb1 |
proteasome (prosome, macropain) subunit, beta type 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of PSMB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:15,695,983...15,718,538
Ensembl chr17:15,695,283...15,720,013
|
|
G |
Psmc2 |
proteasome (prosome, macropain) 26S subunit, ATPase 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PSMC2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:21,990,273...22,008,785
Ensembl chr 5:21,990,281...22,008,785
|
|
G |
Psmc4 |
proteasome (prosome, macropain) 26S subunit, ATPase, 4 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of PSMC4 protein] Hyaluronic Acid analog results in decreased expression of PSMC4 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:27,741,127...27,749,517
Ensembl chr 7:27,741,132...27,749,526
|
|
G |
Psmc5 |
protease (prosome, macropain) 26S subunit, ATPase 5 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PSMC5 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:106,147,011...106,153,938
Ensembl chr11:106,146,980...106,153,946
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of PTK2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RACK1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:48,691,187...48,697,068
Ensembl chr11:48,691,159...48,697,261
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RAN protein] Hyaluronic Acid analog results in decreased expression of RAN protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:129,097,264...129,101,388
Ensembl chr 5:129,097,133...129,101,387
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions increases phosphorylation |
ISO EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] Hyaluronic Acid results in increased phosphorylation of RELA protein Hyaluronic Acid metabolite results in increased phosphorylation of RELA protein Hyaluronic Acid metabolite results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:17879260 PMID:19047049 PMID:23692848 PMID:31226360 PMID:33383130 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Renbp |
renin binding protein |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RENBP protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:72,965,727...72,974,408
Ensembl chr X:72,965,727...72,974,456
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
increases phosphorylation |
ISO |
Hyaluronic Acid results in increased phosphorylation of ROCK1 protein |
CTD |
PMID:16864594 |
|
NCBI chr18:10,064,401...10,182,225
Ensembl chr18:10,064,401...10,182,045
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RPS12 protein] Hyaluronic Acid analog results in decreased expression of RPS12 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:23,661,042...23,664,297
Ensembl chr10:23,661,081...23,663,173
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions decreases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of SCRN1 protein Hyaluronic Acid analog results in decreased expression of SCRN1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:54,451,813...54,543,332
Ensembl chr 6:54,478,158...54,543,474
|
|
G |
Septin11 |
septin 11 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SEPTIN11 protein] Hyaluronic Acid analog results in decreased expression of SEPTIN11 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:93,227,445...93,329,237
Ensembl chr 5:93,241,296...93,324,306
|
|
G |
Septin2 |
septin 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SEPTIN2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:93,406,238...93,437,455
Ensembl chr 1:93,406,686...93,437,982
|
|
G |
Serpinh1 |
serine (or cysteine) peptidase inhibitor, clade H, member 1 |
multiple interactions affects expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SERPINH1 protein] Hyaluronic Acid analog affects the expression of SERPINH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:98,994,583...99,002,321
Ensembl chr 7:98,994,583...99,002,446
|
|
G |
Slc25a11 |
solute carrier family 25 (mitochondrial carrier oxoglutarate carrier), member 11 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SLC25A11 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:70,534,845...70,538,356
Ensembl chr11:70,535,022...70,538,305
|
|
G |
Slmap |
sarcolemma associated protein |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SLMAP protein |
CTD |
PMID:23178681 |
|
NCBI chr14:26,134,323...26,256,103
Ensembl chr14:26,134,323...26,256,086
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276
|
|
G |
Snai2 |
snail family zinc finger 2 |
increases expression |
EXP |
Hyaluronic Acid analog results in increased expression of SNAI2 mRNA; Hyaluronic Acid analog results in increased expression of SNAI2 protein |
CTD |
PMID:20159036 |
|
NCBI chr16:14,523,716...14,527,259
Ensembl chr16:14,523,716...14,527,249
|
|
G |
Sncb |
synuclein, beta |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SNCB protein |
CTD |
PMID:23178681 |
|
NCBI chr13:54,906,673...54,914,435
Ensembl chr13:54,906,673...54,914,408
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SOD1 protein |
CTD |
PMID:23178681 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod3 |
superoxide dismutase 3, extracellular |
affects binding multiple interactions |
EXP |
SOD3 protein binds to Hyaluronic Acid SOD3 protein inhibits the reaction [[Copper co-treated with Hydrogen Peroxide] results in increased degradation of Hyaluronic Acid] |
CTD |
PMID:18165226 |
|
NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SORD protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821
|
|
G |
Sox9 |
SRY (sex determining region Y)-box 9 |
multiple interactions |
EXP |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of SOX9 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of SRC protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Stam2 |
signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of STAM2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:52,582,213...52,632,212
Ensembl chr 2:52,581,676...52,632,293
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of STIP1 protein] Hyaluronic Acid analog results in decreased expression of STIP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:6,998,064...7,017,394
Ensembl chr19:6,998,070...7,017,335
|
|
G |
Tcp1 |
t-complex protein 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TCP1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:13,135,216...13,143,954
Ensembl chr17:13,134,588...13,143,954
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31285260 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions increases abundance |
EXP |
MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression multiple interactions |
EXP |
Hyaluronic Acid metabolite results in increased expression of TLR2 mRNA; Hyaluronic Acid metabolite results in increased expression of TLR2 protein Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR2 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions increases expression increases abundance |
EXP ISO |
Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR4 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR4 protein] Hyaluronic Acid metabolite results in increased expression of TLR4 mRNA; Hyaluronic Acid metabolite results in increased expression of TLR4 protein TLR4 protein results in increased abundance of Hyaluronic Acid [Lipopolysaccharides results in decreased activity of TLR4 protein] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein] |
CTD |
PMID:23692848 PMID:25053413 PMID:31226360 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance increases expression |
ISO EXP |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] [acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of TNF protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of TNF protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of TNF protein TNF mRNA results in increased abundance of Hyaluronic Acid Hyaluronic Acid metabolite results in increased expression of TNF mRNA; Hyaluronic Acid metabolite results in increased expression of TNF protein |
CTD |
PMID:14697411 PMID:23692848 PMID:25053413 PMID:25106431 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip6 |
tumor necrosis factor alpha induced protein 6 |
affects binding multiple interactions |
ISO |
TNFAIP6 protein modified form binds to Hyaluronic Acid TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Hyaluronic Acid] |
CTD |
PMID:12401803 PMID:25561734 |
|
NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698
|
|
G |
Tpm2 |
tropomyosin 2, beta |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TPM2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:43,513,726...43,523,583
Ensembl chr 4:43,514,711...43,523,765
|
|
G |
Tpm3 |
tropomyosin 3, gamma |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TPM3 protein] Hyaluronic Acid analog results in decreased expression of TPM3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:89,979,958...90,008,209
Ensembl chr 3:89,979,956...90,008,209
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of TPT1 protein |
CTD |
PMID:23178681 |
|
NCBI chr14:76,082,771...76,085,743
Ensembl chr14:76,082,533...76,085,965
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TUBB5 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:36,144,812...36,149,193
Ensembl chr17:36,144,813...36,149,198
|
|
G |
Vcp |
valosin containing protein |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of VCP protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:42,979,964...43,000,507
Ensembl chr 4:42,979,963...43,000,507
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Hyaluronic Acid promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] |
CTD |
PMID:20067761 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vim |
vimentin |
increases expression multiple interactions affects expression |
EXP ISO |
Hyaluronic Acid analog results in increased expression of VIM protein Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide affects the expression of VIM protein] Hyaluronic Acid analog affects the expression of VIM protein |
CTD |
PMID:20159036 PMID:23178681 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Vps33a |
VPS33A CORVET/HOPS core subunit |
multiple interactions increases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of VPS33A protein] Hyaluronic Acid analog results in increased expression of VPS33A protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:123,666,820...123,711,104
Ensembl chr 5:123,666,722...123,711,101
|
|
G |
Wdr1 |
WD repeat domain 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of WDR1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:38,684,149...38,720,265
Ensembl chr 5:38,684,156...38,720,564
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of YARS1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:129,083,595...129,113,033
Ensembl chr 4:129,083,553...129,113,400
|
|